<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Yusuf, Salim</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Polypill May Offer Increased Protection against Cardiovascular Disease in Patients with Average Risk Factors</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">Results of the Indian Polycap Study [TIPS; NCT00443794] indicate that it may be possible for individuals who have average risk factors for cardiovascular disease to significantly reduce their risk for heart disease and stroke through the use of a single pill—the Polycap™—which combines low doses of thiazide (12.5 mg), atenolol (50 mg), ramipril (5 mg), simvastatin (20 mg), and aspirin (100 mg).</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>